Tema Oncology ETF (NASDAQ:CANC – Get Free Report) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 6,200 shares, a growth of 87.9% from the September 30th total of 3,300 shares. Based on an average daily volume of 8,500 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.2% of the shares of the company are short sold. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 8,500 shares, the days-to-cover ratio is currently 0.7 days.
Institutional Investors Weigh In On Tema Oncology ETF
Several institutional investors and hedge funds have recently added to or reduced their stakes in CANC. Banque Transatlantique SA purchased a new stake in Tema Oncology ETF in the first quarter worth approximately $39,000. Jane Street Group LLC purchased a new stake in Tema Oncology ETF in the first quarter worth approximately $213,000. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Tema Oncology ETF by 658.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 957,475 shares of the company’s stock worth $23,673,000 after acquiring an additional 831,281 shares during the last quarter.
Tema Oncology ETF Trading Up 0.7%
Shares of CANC stock opened at $30.97 on Monday. Tema Oncology ETF has a 12-month low of $20.10 and a 12-month high of $31.55. The firm’s 50 day moving average is $28.52 and its 200 day moving average is $26.30. The stock has a market capitalization of $86.41 million, a P/E ratio of 20.39 and a beta of 1.00.
About Tema Oncology ETF
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Featured Articles
- Five stocks we like better than Tema Oncology ETF
- Asset Allocation Strategies in Volatile Markets
- Is Lemonade Stock Set for a Big Squeeze After Earnings?
- What Are the FAANG Stocks and Are They Good Investments?
- Caterpillar Stock Could Top $650 by Year’s End
- How to Start Investing in Real Estate
- ServiceNow’s 5-for-1 Split Is a Signal for Investors to Buy
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
